A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04637009|
Recruitment Status : Active, not recruiting
First Posted : November 19, 2020
Last Update Posted : February 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants ≥18 years of age with relapsed or refractory (R/R) acute myeloid leukemia (AML) or other myeloid neoplasms where approved therapies have failed or for whom known life-prolonging therapies are not available. The AML population includes de novo AML, secondary AML, and myelodysplastic syndrome (MDS)-transformed into AML. Other myeloid neoplasms include accelerated phase myeloproliferative neoplasms (MPN), and chronic or accelerated phase MPN-unclassifiable (MPN-U) and MDS-MPN. Blast crisis phase of MPNs are considered secondary AML and will be included in the AML cohort.
Part 1 is a multicenter, sequential group treatment feasibility study with 1 treatment arm and no masking (dose escalation). Part 2 is a multicenter, two-stage, multiple group, dose confirmation study with 1 treatment arm and no masking (exploratory dose expansion).
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm||Drug: TAS1553||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms|
|Actual Study Start Date :||December 21, 2020|
|Estimated Primary Completion Date :||August 31, 2023|
|Estimated Study Completion Date :||August 31, 2023|
Experimental: Part 1 (dose escalation)
Oral administration of TAS1553 once daily at specific time points.
Form: tablet; Route of Administration: oral
Experimental: Part 2 (dose expansion)
Oral administration of TAS1553 once daily at specific time points.
Form: tablet; Route of Administration: oral
- Safety: Number of participants with treatment-emergent adverse events in Part 1 [ Time Frame: Up to 12 months ]
- Safety: Number of participants with dose-limiting toxicities in Part 1 [ Time Frame: Up to 12 months ]
- Response rate in Cohort 1 (AML): Number of participants with complete response (CR) + complete response with partial hematological recovery (CRh), and with CR + incomplete blood count recovery (CRi) in Part 2 [ Time Frame: Up to 33 months ]
- Response rate in Cohort 2 (other myeloid neoplasms): Number of participants with overall response rate (ORR) of CR + partial response (PR) in Part 2 [ Time Frame: Up to 33 months ]
- Pharmacokinetic parameter: Area under the curve (AUC) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
- Pharmacokinetic parameter: Maximum plasma concentration (Cmax) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
- Pharmacokinetic parameter: Minimum plasma concentration (Cmin) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
- Pharmacokinetic parameter: Time to reach maximum plasma concentration (Tmax) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
- Pharmacokinetic parameter: Half-life (t½) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
- Hematological improvement: Number of participants in Cohort 2 (other myeloid neoplasms) with hematological improvement in Part 2 [ Time Frame: Up to 33 months ]
- Time to response (TTR): Number of days from the first dose to the first documented evidence of response [ Time Frame: Up to 33 months ]
- Duration of response (DOR): Number of days from the start of response until disease progression or relapse [ Time Frame: Up to 33 months ]
- Overall survival (OS): Number of days from date of first dose until death due to any cause [ Time Frame: Up to 33 months ]
- Safety: Number of participants with treatment-emergent adverse events in Part 2 [ Time Frame: Up to 33 months ]
- Pharmacodynamic biomarker: Change from baseline in deoxyadenosine triphosphate (dATP) pool levels in peripheral blood mononuclear cells (PBMCs) [ Time Frame: At specific timepoints from predose up to Day 2 of Cycle 2 (28 days per cycle) ]
- Pharmacodynamic biomarker: Change from baseline in phosphorylated checkpoint kinase 1 (pCHK1) levels in bone marrow [ Time Frame: At specific timepoints from predose up to Day 2 of Cycle 2 (28 days per cycle) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Capable of giving signed informed consent.
- Participant must be 18 years of age or older, at the time of signing the informed consent.
- Life expectancy of at least 12 weeks as assessed by the investigator.
- Participants with R/R AML or other myeloid neoplasms where approved therapies have failed or for whom known life-prolonging therapies are not available. The AML population includes de novo AML, secondary AML, and MDS transformed into AML. Other myeloid neoplasms include accelerated phase MPN, and chronic or accelerated phase MPN-U and MDS-MPN. Blast crisis phase of MPN, MPN-U, and MDS-MPN are considered secondary AML and will be included in the AML cohort.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Have platelet count ≥10,000/μL (transfusions to achieve this level are allowed).
- Have adequate renal function as demonstrated by a 24-hour urine measured creatinine clearance ≥60 mL/min.
Adequate hepatic function as evidenced by:
- aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN)
- alanine aminotransferase (ALT) ≤3×ULN
- total bilirubin ≤1.5×ULN.
- Participants must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study.
- Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
- Participants who have MPN, MPN-U, or MDS/MPN and display hypoplastic bone marrow and would also not ordinarily benefit from cytoreductive therapy such as hydroxyurea (HU).
Participants with highly proliferative disease are excluded as follows:
- Part 1/AML: white blood cells (WBC) >20,000/μL and >50% blasts in blood. Measures to reduce WBC, such as HU treatment within the last 2 weeks and cytotoxic chemotherapy within the last 4 weeks are not allowed to meet this eligibility criterion.
- Part 1/other myeloid neoplasms: WBC >20,000/μL. A short course of HU may be used to meet this eligibility criterion, as long as HU is discontinued 96 hours and any encountered drug-related toxicity must be resolved to Grade ≤1 before the first dose of study treatment.
- Part 2/Cohort 1, AML: WBC>20,000/μL and >50% blasts in blood. A short course of HU may be used to meet this eligibility criterion, as long as HU is discontinued 96 hours, and any encountered drug-related toxicity must be resolved to Grade ≤1 before the first dose of study treatment.
- Part 2/Cohort 2, other myeloid neoplasms: Specific WBC exclusion criterion not defined. A short course of HU may be used to reduce WBC if judged to be necessary by the investigator, as long as HU is discontinued 96 hours and any encountered drug-related toxicity must be resolved to Grade ≤1 before the first dose of study treatment.
- Known clinically active central nervous system (CNS) leukemia.
- Diagnosis of BCR-ABL-positive leukemia, acute promyelocytic leukemia (M3 AML or APML), or juvenile myelomonocytic leukemia (JMML).
- Second malignancy requiring active systemic therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
- Ongoing Grade ≥3 Graft Versus Host Disease (GVHD), or any grade GVHD requiring active treatment (for example, calcineurin inhibitors, ≥5mg/day prednisone or other steroid equivalent, or other immunosuppressive agents). (Note: Prednisone at any dose for other indications is allowed).
- Advanced human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; Inactive hepatitis carrier status and participants with laboratory evidence of no active replication and participants on antiviral medication(s) who have a viral load below limit of detection will be permitted.
- Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of non-compliance with the protocol.
- Active infection resistant to antibiotics; or non-leukemia-associated pulmonary disease requiring >2 liters per minute oxygen or any other condition that puts the participant at an imminent risk of death.
- 24-hour urinary protein excretion ≥1g or urinalysis of 2+proteinuria.
History of, or at risk for, cardiac disease, as evidenced by any of the following conditions:
- Abnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan at Screening.
- Congestive cardiac failure of Class ≥III severity according to New York Heart Association (NYHA) functional classification defined as patients with marked limitation of activity and who are comfortable at rest, while Class IV patients have symptoms of heart failure at rest.
- Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
- Ventricular arrhythmias including ventricular bigeminy, clinically significant brady arrhythmias such as sick sinus syndrome, third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other clinically significant arrhythmias.
- Screening 12-lead electrocardiogram (ECG) with measurable QTcF interval of ≥470 msec (Fridericia's formula should be used).
- Known hypersensitivity to TAS1553 or any of its components.
- Allogenic hematopoietic stem cell transplantation (HSCT) within 180 days of the first dose of TAS1553, or participants on immunosuppressive therapy post HSCT at the time of screening (calcineurin inhibitors or similar must be discontinued ≥4 weeks prior to the time of study drug initiation).
- Treated with any systemic anticancer therapy within 2 weeks of the first dose of study treatment. Any encountered treatment-related toxicities (excepting alopecia) must be resolved to Grade 1 or less.
- Phase 1 Part 1 only: participants who require concomitant use of strong CYP3A4 inducers.
- Inability to swallow oral medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04637009
|United States, Alabama|
|University of Alabama - Birmingham Comprehensive Cancer Center|
|Birmingham, Alabama, United States, 35233|
|United States, Arizona|
|HonorHealth Research Institute|
|Scottsdale, Arizona, United States, 82528|
|United States, California|
|University of Southern California Keck School of Medicine|
|Los Angeles, California, United States, 90033|
|United States, Georgia|
|Augusta University - Georgia Cancer Center|
|Augusta, Georgia, United States, 30912|
|United States, Kentucky|
|Norton Cancer Institute|
|Louisville, Kentucky, United States, 40241|
|United States, New York|
|Weill Cornell Medicine and New York - Presbyterian Hospital|
|New York, New York, United States, 10065|
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Institute|
|Cleveland, Ohio, United States, 44195|
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|University of Alberta Hospital - Hematology Research|
|Edmonton, Alberta, Canada, T6G 2V2|
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 2L7|
|Study Director:||Study Director||Astex Pharmaceuticals, Inc.|
|Responsible Party:||Astex Pharmaceuticals, Inc.|
|Other Study ID Numbers:||
|First Posted:||November 19, 2020 Key Record Dates|
|Last Update Posted:||February 21, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
MDS/MPN, unclassifiable in chronic phase
Accelerated phase MPN
Chronic neutrophilic leukemia (CNL), accelerated phase
Polycythemia vera (PV), accelerated phase
Primary myelofibrosis (PMF), accelerated phase
Essential thrombocythemia (ET), accelerated phase
Chronic eosinophilic leukemia, not otherwise specified (NOS), accelerated phase
Chronic myelomonocytic leukemia (CMML)
Atypical chronic myeloid leukemia (aCML), BCR-ABL1-negative
MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Bone Marrow Diseases